Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis

IMPORTANCE: Immune checkpoint inhibitors of programmed cell death 1 (PD-1) and its ligand (PD-L1) have led to a paradigm shift in cancer treatment. Understanding the clinical efficacy and safety profile of these drugs is necessary for treatment strategy in clinical practice. OBJECTIVE: To assess the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Autores principales: Duan, Jianchun, Cui, Longgang, Zhao, Xiaochen, Bai, Hua, Cai, Shangli, Wang, Guoqiang, Zhao, Zhengyi, Zhao, Jing, Chen, Shiqing, Song, Jia, Qi, Chuang, Wang, Qing, Huang, Mengli, Zhang, Yuzi, Huang, Depei, Bai, Yuezong, Sun, Feng, Lee, J. Jack, Wang, Zhijie, Wang, Jie
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990765/
https://ncbi.nlm.nih.gov/pubmed/31876895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.5367
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares